Stock Forecast: The Market is Sleeping on Eli Lilly’s Next $1 Trillion Opportunity

Eli Lilly (NYSE:LLY | LLY Price Prediction) has quietly transformed itself into the first pharmaceutical company ever valued above $1 trillion, and yet the market may still be underpricing what comes next. Retatrutide, orforglipron, and a stacked oncology and neuroscience bench point to a growth runway that our proprietary model believes justifies a materially higher stock price over the next twelve months.

Our 24/7 Wall St. price target for Eli Lilly is $1,415.89, implying 19.67% upside from the current $1,183.16 quote. The recommendation is buy at 90% confidence. The model combines accelerating earnings, defensive beta, and pipeline blockbuster optionality.

24/7 Wall St. Price Target Summary

A Trillion-Dollar Milestone, Then a Cool-Off

Lilly became the first pharmaceutical firm worth $1 trillion in late May, and shares are up 69.79% over the past year and 10.63% year to date. The stock is down 3.82% over the past week and sitting about 5% below the 52-week high of $1,247.66.

That pullback follows a Q2 report that was one of the cleanest earnings reports in large-cap pharma this cycle: revenue of $22.974 billion (up 47.67%), EPS of $8.38 beating expectations, and management raising FY26 revenue guidance to $85 to $87 billion.

The Case for $1,600+

The bull scenario points to $1,627.17, or 37.53% upside. Retatrutide, the triple GLP-1/GIP/glucagon agonist, produced weight loss approaching bariatric surgery levels across three positive Phase 3 trials, with a BLA submission planned for Q1 2027. AJMC called it a “trillion-dollar drug”, defensible given Lilly already owns roughly 6 out of 10 U.S. obesity prescriptions.

Foundayo, the only oral GLP-1 approved for anytime dosing, jumped from 8,000 to 36,000 prescribers in a single quarter. Add in the Medicare GLP-1 Bridge Program covering 20 million eligible Americans at $50 per month, and the analyst consensus target of $1,310.90 looks conservative.

What Could Go Wrong

The bear case pins fair value at $1,174.96, essentially flat. Risks include U.S. realized prices falling roughly 9% excluding rebate adjustments, Novo Nordisk competing for share, and manufacturing capacity constraints.

The Q2 tax rate spiked to 23.3% because of $2.78 billion in IPR&D charges from four acquisitions. Insider activity has skewed to net selling across 14 recent transactions. The IPR&D drag reflects aggressive pipeline building (Orna, Ajax, Centessa, Kelonia), and gross margin expanded to 85.8%.

How Lilly Compares to Novo Nordisk and Merck

Novo Nordisk (NYSE:NVO) trades at a forward P/E of just 14 with quarterly revenue growth of only 2.1% and earnings contracting 20.6% year over year. Lilly’s premium multiple is earned.

Merck (NYSE:MRK) offers a useful big-pharma contrast. Merck’s forward P/E is 50, with revenue growth of only 5.1% and EPS growth of negative 19.3%. Lilly’s 32x forward earnings paired with 47.67% revenue growth compares favorably on a growth-adjusted basis.

Eli Lilly Price Prediction 2026-2030

The 24/7 Wall St. model output is a buy rating at 90% confidence, with a price target of $1,415.89. Retatrutide is the tipping factor. If the BLA lands on time and the label spans obesity, sleep apnea, and osteoarthritis, the bull scenario at $1,627 becomes the base case. The thesis weakens if U.S. pricing erosion accelerates past 15% or Novo delivers a surprise oral formulation win.

These projections assume Lilly executes on retatrutide’s launch and continues expanding Foundayo internationally. Significant upside or downside could result from GLP-1 competitive dynamics and U.S. drug-pricing policy.

Contact [email protected] for any questions or corrections.